A

Akero Therapeutics

D
AKRO
USD
-0.405
(-1.1476%)
Market Closed
23,785.00
Volume
-3.77
EPS
-
Div Yield
-10.140988
P/E
2,422,091,853.29
Market Cap
Today
-1.1476%
1 Week
13.006%
1 Month
30.411%
6 Months
58.590%
12 Months
124.053%
Year To Date
49.145%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
S
SNX
1.16
(0.9375%)
USD
C
COMP
0.43
(6.6512%)
USD
B
BAL
(%)
USD

Title:
Akero Therapeutics

Sector:
Healthcare
Industry:
Biotechnology
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.
Do you need help or have a question?
Contact Us